scholarly journals Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease

2021 ◽  
Vol 9 ◽  
pp. 232470962199076
Author(s):  
Alexander Dills ◽  
Okechukwu Obi ◽  
Kevin Bustos ◽  
Jesse Jiang ◽  
Shweta Gupta
Keyword(s):  
Prostate Cancer ◽  
Serine Proteases ◽  
Cancer Genetics ◽  
Performance Status ◽  
Distant Metastases ◽  
The United States ◽  
Cutaneous Metastasis ◽  
Common Disease ◽  
Cutaneous Metastases ◽  
Rare Presentation

Prostate cancer is the most common cancer affecting men in the United States and the second greatest cause of cancer-related death. Metastases usually occur to bone followed by distant lymph nodes and then viscera. Cutaneous metastases are extremely rare. Their presence indicates advanced disease and a poor prognosis. As they are highly variable in appearance and may mimic a more benign process, biopsy is essential for identification. Serine proteases, particularly human tissue kallikreins, may play an important role in promoting metastasis and facilitate infiltration of the skin. Individual cancer genetics may predispose to more aggressive cancer and thus earlier and more distant metastases. In this article, we report our case of a 67-year-old man with a 4-year history of castrate-resistant prostate cancer with cutaneous metastases confirmed by histology. Despite multiple lines of systemic therapy, the patient suffered progressive disease with worsening performance status and was enrolled in hospice.

scholarly journals Metastatic Prostate Cancer Involving the Sphenoid Sinus and Mandible

2021 ◽  
pp. 014556132110060
Author(s):  
Fadlullah Ba’th ◽  
Tanisha Hutchinson ◽  
Annie Meares ◽  
David Hamlar
Keyword(s):  
Prostate Cancer ◽  
Sphenoid Sinus ◽  
Metastatic Prostate Cancer ◽  
The United States ◽  
Endoscopic Examination ◽  
Atypical Presentation ◽  
Rare Presentation ◽  
The Third ◽  
Pathological Evaluation ◽  
Low Threshold

Prostate cancer is the third most leading cause of cancer in men in the United States. Although expected metastatic spread to bone, liver, and lymph nodes are often monitored, there are other rare presentations that can occur. This case report demonstrates a rare presentation of prostate cancer spreading to the paranasal sinuses and orbit. Not only did this case have an atypical presentation mimicking infection, the diagnosis was also only achieved through pathological evaluation after an endoscopic examination and biopsy. This case demonstrates the importance of a low threshold for endoscopic examinations in uncertain sinonasal presentations, and consistent biopsies when performing endoscopic examinations.

Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time

2018 ◽  
pp. 355-362 ◽  
Author(s):  
Daniel E. Spratt ◽  
Deaglan J. McHugh ◽  
Michael J. Morris ◽  
Alicia K. Morgans
Keyword(s):  
Prostate Cancer ◽  
New Technologies ◽  
Postoperative Radiotherapy ◽  
The United States ◽  
Common Disease ◽  
Recurrent Prostate Cancer ◽  
Systemic Treatments ◽  
Effect Of Therapy ◽  
New Gene ◽  
The Right

Biochemically recurrent prostate cancer is an increasingly common disease state, with more than 25,000 cases occurring annually in the United States. Fortunately, progress continues to be made to more effectively identify metastatic disease, optimize existing therapies, and develop new technologies and therapeutic strategies for the timing and delivery of systemic treatments to improve outcomes. This review covers three topics related to the diagnosis and treatment of men with biochemical recurrence (BCR). First, we provide an update on the state of the rapidly evolving field of molecular imaging and its place in practice. Second, we describe validated clinicopathologic methods to risk stratify patients with biochemically recurrent disease, including new gene expression classifiers, to personalize postoperative radiotherapy (RT) timing. Last, we define our approach to optimal management with systemic therapy, including identifying the patients who may benefit most and balancing the duration and timing of treatment with consideration of the effect of therapy on quality of life (QOL) and medical complications associated with treatment.

Detailed Analysis of Neutropenic Risk Factors in Patients with Prostate Cancer Treated with Chemotherapy.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3804-3804
Author(s):  
Elizabeth R. Laber ◽  
Damian A. Laber
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Performance Status ◽  
The United States ◽  
Severe Neutropenia ◽  
Ecog Performance Status ◽  
Group 2 ◽  
Grade 3 ◽  
Baseline Psa ◽  
Group 1

Abstract Background: Although thousands of patients (Pts) receive chemotherapy every year in the United States, only few retrospective studies have been done to address the risk factors for chemotherapy (CT) induced neutropenia in patients with cancer. The data in androgen-independent prostate cancer (AIPC) patients is extremely scarce. We decided to perform a retrospective analysis of patients with metastatic AIPC treated with chemotherapy in an open phase II clinical trial looking for predictive factors for neutropenia. Methods: We reviewed the records of all patients with AIPC who completed at least 2 cycles of CT with cyclophosphamide 50 mg/m2, etoposide 50 mg/m2 and estramustine 280 mg orally every night for 14 days out of a 28 day-cycle. We divided the patients into 2 groups according to neutropenia grade 3–4 (Group 1) versus 0–2 (Group 2). Risk factors reviewed included age, number of organs involved with metastases, number of bone metastasis, prior radiotherapy (RT) to the prostate/pelvis, prior number of areas treated with palliative RT, prior CT regimens, baseline PSA, absolute neutrophil count (ANC) and ECOG performance status (PS). Results: See table and figures. Group 1 2 Neutropenia Grade 3–4 0–2 # of Pts 7 11 Age 68 (58–86) 63 (52–74) # organs involved 2.1 1.6 # bone metastases 10.9 9.5 RT prostate/pelvis 0.1 0.4 # palliative RT courses 1 0.6 # prior CT regimens 0.4 0.2 Baseline ANC 3.6 3.8 Baseline PS ECOG 1.3 1.4 Baseline PSA 584 (26–2268) 157 (37–65) Figure Figure Conclusions: Average age and PSA were the only risk factors that were different between the patients who developed severe neutropenia and the ones who did not, albeit not statistically significant. Studies with a larger sample size may detect clinically and statistically significant differences.

scholarly journals Multiple Cutaneous Metastases as Initial Presentation in Advanced Colon Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Sudheer Nambiar ◽  
Asha Karippot
Keyword(s):  
Advanced Colorectal Cancer ◽  
Clinical Manifestations ◽  
Colon Adenocarcinoma ◽  
Distant Metastases ◽  
Cutaneous Metastasis ◽  
Ascending Colon ◽  
Visceral Metastasis ◽  
Cutaneous Metastases ◽  
Advanced Colon Cancer ◽  
Metastatic Lesions

Skin metastases from advanced colorectal cancer are relatively rare and occur most often when the cancer is advanced, following the spread to other organs. Cutaneous metastases occur in about 3% of advanced colorectal cancers. We present an extremely rare case of a 68-year-old woman with advanced ascending colon adenocarcinoma that presented with multiple rapidly progressing painless cutaneous metastatic lesions with no other distant metastases. Of all the tumors, breast cancer most commonly spreads as cutaneous metastasis is followed by lung, colorectal, renal, ovarian, and bladder cancers. Cutaneous metastases can present in a variety of clinical manifestations, such as a rapidly growing painless dermal or subcutaneous nodule with intact overlying epidermis or as ulcers. In cases where the cutaneous deposit is isolated, as in visceral metastasis, there is a role for radical management such as wide local excision and reconstruction. In our patient, since she had multiple cutaneous metastases she began treatment with palliative systemic combination chemotherapy.

Overall survival of black and white men with metastatic castrate-resistant prostate cancer: A retrospective analysis across 20 years in the largest healthcare trust in the United Kingdom.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 35-35
Author(s):  
Kenrick Ng ◽  
Peter Wilson ◽  
Katherine Mutsvangwa ◽  
Jonathan Shamash
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Clinical Trials ◽  
Bone Metastases ◽  
Performance Status ◽  
Cohort Analysis ◽  
The United States ◽  
Castration Resistant Prostate Cancer ◽  
Real World Data ◽  
Black Patients

35 Background: Prostate cancer in Black (B) men has been associated with poorer outcomes than their White (W) counterparts. However, this perception has been derived from studies conducted predominantly in the localized prostate cancer setting, were based on data derived from clinical trials and usually conducted solely within the United States. Methods: We reviewed the outcomes of cases with metastatic castration resistant prostate cancer (mCRPC) treated at St Bartholomew’s Hospital – the UK's largest Healthcare Trust - between 1997-2016. Statistical analyses were conducted using Intercooled Stata 8.2 (State College, TX, USA). Results: We identified 425 cases of mCRPC in the 20 year period. A substantial minority of our patients, 103 (24%) were Black (B), and the remainder White (W). Characteristics were matched in age (73 years in both groups), proportion enrolled in clinical trials (33% in both groups) and median PSA (65.6,B vs 78,W, p=0.86), with a larger proportion of Black patients with a ECOG Performance Status ≥ 2 (19%,B vs 9%,W). In the total cohort analysis, the median Overall Survival (OS) was 25.5 months (B) vs 21.8 months (W), (Hazard Ratio, HR=0.81,p=0.08). For the subpopulation who received chemotherapy at some point of their treatment (n=306), survival was comparable in both groups (median OS 23.8 months, B vs 22.8 months, W, HR=0.97,p=0.82). Interestingly, there was a trend to prolonged survival in the Black population in those who only received hormone therapy (n=106) throughout their treatment course; 39.7 months (B) vs 17.1 months (W), HR=0.54, p=0.019. In a multivariate analysis for prognostic factors for survival from mCRPC therapy considering ethnicity (HR 0.81 p=0.08), time from diagnosis to castrate resistance (HR 1.02, p=0.136), presence of bone metastases at CRPC diagnosis (HR 1.89,p=0.001) – only bone metastases were significant. Conclusions: In the first set of real-world data in a study conducted outside the US, we demonstrate that Black patients do not do worse than White patients with mCRPC. The study suggests that there is a greater margin of benefit of hormone-based therapy in the Black subpopulation.

scholarly journals Recurrence of Prostate Cancer with Cutaneous Metastasis after Radical Prostatectomy

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Parth Patel ◽  
Jay Patel ◽  
Sameer Siddiqui
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Radical Prostatectomy ◽  
Lower Leg ◽  
Cutaneous Metastasis ◽  
Prostatic Adenocarcinoma ◽  
Recurrent Prostate Cancer ◽  
Cutaneous Metastases ◽  
Cutaneous Manifestations

While cutaneous metastases are already extremely rare in primary metastatic prostatic adenocarcinoma, cutaneous manifestations in recurrent prostate cancer have rarely been described prior to this report. Here we present the case report of a 93-year-old male who underwent radical prostatectomy but eventually suffered from a previously undescribed recurrence of prostatic adenocarcinoma with distant cutaneous metastases to proximal right lower leg.

scholarly journals Cutaneous Metastasis in the Setting of Both Colon and Breast Primary Malignancies

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Mary Junak ◽  
Hunter Jecius ◽  
Jennifer Erdrich ◽  
Shiro Kikuchi
Keyword(s):  
Ductal Carcinoma ◽  
Case Reports ◽  
Colon Adenocarcinoma ◽  
The United States ◽  
Punch Biopsy ◽  
Left Breast ◽  
Cutaneous Metastasis ◽  
Cutaneous Lesions ◽  
Cutaneous Metastases ◽  
Colonic Primary

Colorectal cancer (CRC) is the third most diagnosed cancer in the United States, and many patients unfortunately have metastases at the time of their diagnosis. Cutaneous metastases of CRC have been reported in few journals and primarily as case reports due to their rarity. Here, we present the case of an 83-year-old woman with recently resected colon cancer, T4aN1bMx stage IIIB. She presented to our clinic for evaluation of a right midback mass, and a punch biopsy revealed dermal involvement by invasive, poorly differentiated carcinoma with epidermoid features. The mass was excised, and we ordered a PET scan in search of the primary tumor, which at that time was suspected to be of skin cancer origin. Surprisingly, this revealed a second malignancy triple-negative invasive ductal carcinoma of the left breast. The back mass stained positive for CK20, which was compatible with a metastasis from a colonic primary. After initially declining adjuvant therapy, the patient completed one cycle of capecitabine and oxaliplatin, which she tolerated poorly. She continued to further decline, developed widespread cutaneous metastases, and went home on hospice. Cutaneous lesions are an exceedingly rare site of metastasis for colon adenocarcinoma, and their clinical presentation can vary widely. It is important for providers to investigate any new skin lesion in a patient with a recent or remote history of malignancy, even if there were no sites of distant metastasis at initial diagnosis.

scholarly journals Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

2010 ◽  
Vol 107 (5) ◽  
pp. 2136-2140 ◽  
Author(s):  
Jianfeng Xu ◽  
Siqun Lilly Zheng ◽  
Sarah D. Isaacs ◽  
Kathleen E. Wiley ◽  
Fredrik Wiklund ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
The United States ◽  
Recessive Model ◽  
Independent Study ◽  
Common Disease ◽  
Low Grade ◽  
Significance Level ◽  
Aggressive Disease ◽  
Aging Men

Autopsy studies suggest that most aging men will develop lesions that, if detected clinically, would be diagnosed as prostate cancer (PCa). Most of these cancers are indolent and remain localized; however, a subset of PCa is aggressive and accounts for more than 27,000 deaths in the United States annually. Identification of factors specifically associated with risk for more aggressive PCa is urgently needed to reduce overdiagnosis and overtreatment of this common disease. To search for such factors, we compared the frequencies of SNPs among PCa patients who were defined as having either more aggressive or less aggressive disease in four populations examined in the Genetic Markers of Susceptibility (CGEMS) study performed by the National Cancer Institute. SNPs showing possible associations with disease severity were further evaluated in an additional three independent study populations from the United States and Sweden. In total, we studied 4,829 and 12,205 patients with more and less aggressive disease, respectively. We found that the frequency of the TT genotype of SNP rs4054823 at 17p12 was consistently higher among patients with more aggressive compared with less aggressive disease in each of the seven populations studied, with an overall P value of 2.1 × 10−8 under a recessive model, exceeding the conservative genome-wide significance level. The difference in frequency was largest between patients with high-grade, non–organ-confined disease compared with those with low-grade, organ-confined disease. This study demonstrates that inherited variants predisposing to aggressive but not indolent PCa exist in the genome, and suggests that the clinical potential of such variants as potential early markers for risk of aggressive PCa should be evaluated.

Sign in / Sign up

Export Citation Format

Share Document